Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio s Q3 Revenue Rises, Net Income Falls

NEW YORK, Nov. 4 (GenomeWeb News) - Harvard Bioscience yesterday reported a 4-percent increase in third-quarter revenues and a 31-percent drop in net income.


For the quarter ended Sept. 30, the company's apparatus and instrumentation unit, which it is retaining, brought in revenue of $17.2 million for the quarter, up from $16.5 million in the prior-year period.


Harvard Bio did not disclose revenue for its capital equipment segment, which it plans to divest and has classified as discontinued operations held for sale.


The company posted net income of $661,000 for the third quarter, down from $957,000 in the year-ago period.


Research and development expenses fell by 14 percent to $700,000 for the quarter from $800,000 in the same period of 2004.


The company ended the quarter with cash and cash equivalents of $11.3 million.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.